Abstract
The once-weekly glucagon-like peptide 1 receptor agonists (QW GLP1RA) represent a major advancement in diabetes pharmaco-therapeutics. This review describes the basic, clinical, and comparative pharmacology of this novel class of drugs. It highlights the clinical placement and posology of these drugs.
Keywords:
Albiglutide, dulaglutide, exenatide QW, semaglutide..
MeSH terms
-
Delayed-Action Preparations
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Administration Schedule
-
Exenatide
-
Glucagon-Like Peptide 1 / administration & dosage
-
Glucagon-Like Peptide 1 / analogs & derivatives
-
Glucagon-Like Peptide-1 Receptor / agonists*
-
Glucagon-Like Peptides / administration & dosage
-
Glucagon-Like Peptides / analogs & derivatives
-
Humans
-
Hypoglycemic Agents / administration & dosage*
-
Immunoglobulin Fc Fragments / administration & dosage
-
Incretins / administration & dosage*
-
Peptides / administration & dosage
-
Recombinant Fusion Proteins / administration & dosage
-
Venoms / administration & dosage
Substances
-
Delayed-Action Preparations
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Immunoglobulin Fc Fragments
-
Incretins
-
Peptides
-
Recombinant Fusion Proteins
-
Venoms
-
rGLP-1 protein
-
Glucagon-Like Peptides
-
Glucagon-Like Peptide 1
-
Exenatide
-
dulaglutide